financetom
Business
financetom
/
Business
/
Wendy's Projects up to $18 Billion in Sales by 2028, Eyes Restaurant Count Expansion
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Wendy's Projects up to $18 Billion in Sales by 2028, Eyes Restaurant Count Expansion
Mar 6, 2025 12:54 PM

03:37 PM EST, 03/06/2025 (MT Newswires) -- Wendy's (WEN) projected an acceleration in annual sales growth on a long-term horizon from its 2025 growth target, and said it expects to add roughly 1,000 restaurants by 2028.

Systemwide sales are projected to rise 5% to 6% annually over the long term and reach between $17.5 billion and $18 billion in 2028, according to a presentation prepared for its annual investor day that was held Thursday.

That compares with a 2025 sales growth guidance of 2% to 3% that Wendy's affirmed on Thursday. In February, Wendy's reported systemwide sales climbed 3.1% in 2024 to $14.49 billion.

Net restaurant units are expected to climb 3% to 4% annually over the long term and reach between 8,100 and 8,300 in 2028. That compares with a restaurant count of 7,240 at the end of 2024, which was flat from 2023.

"We are investing in building new restaurants around the globe and deploying technology that will enhance the customer experience and increase restaurant profitability," Chief Financial Officer Ken Cook said in a statement.

The company reiterated its current-year non-GAAP earnings per share guidance of $0.98 to $1.02. Analysts on average are modeling for adjusted EPS of $1.01 this year, according to a FactSet survey.

Over the long term, Wendy's expects adjusted earnings before interest, taxes, depreciation and amortization to rise 7% to 8% annually and reach $650 million to $700 million by 2028. Adjusted EBITDA increased just 1.4% in 2024 to $543.6 million.

Management continues to expect adjusted EBITDA will range between $550 million and $560 million in 2025.

Price: 15.16, Change: +0.21, Percent Change: +1.37

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Cathie Wood's ARK Invest scoops up nearly 10,000 Reddit shares in debut
Cathie Wood's ARK Invest scoops up nearly 10,000 Reddit shares in debut
Mar 22, 2024
(Reuters) - Popular investor Cathie Wood's ARK Invest bought nearly 10,000 shares of Reddit ( RDDT ) in the social media platform's strong market debut on Thursday, an email from the asset manager showed. A total of 9,982 shares of the loss-making company was added to ARK Next Generation Internet ETF ( ARKW ) and ARK Fintech Innovation ETF (...
Once a beacon of stability, Vietnam to name third president in a year
Once a beacon of stability, Vietnam to name third president in a year
Mar 22, 2024
HANOI, March 22 (Reuters) - Communist-ruled Vietnam is seeking its third president in little more than a year after the resignation of Vo Van Thuong, who was only elected last year after the sudden dismissal of his predecessor. With accumulated foreign direct investment higher than its gross domestic product, Vietnam's stability is crucial to multinationals with large operations in the...
Japan's union group Rengo announces biggest wage hikes on record
Japan's union group Rengo announces biggest wage hikes on record
Mar 22, 2024
TOKYO (Reuters) -Japanese firms have agreed to raise pay by 5.25% this year, the biggest rise under comparable data since 2013, the country's largest union group Rengo confirmed on Friday. The results of the closely-watched wage negotiations are announced in several stages, in which the blue-chip firms are first to wrap up their talks in mid-March. The second announcement on...
Hutchmed Begins Registration Stage for Phase 2/3 Trial of Investigational Autoimmune Disorder Drug
Hutchmed Begins Registration Stage for Phase 2/3 Trial of Investigational Autoimmune Disorder Drug
Mar 22, 2024
05:04 AM EDT, 03/22/2024 (MT Newswires) -- Hutchmed ( HCM ) said late Thursday it has started the registration stage for a phase 2/3 clinical trial of investigational drug sovleplenib for adult patients with warm antibody autoimmune hemolytic anemia in China. The move follows positive data from the proof-of-concept phase 2 stage of the trial and a consultation with the...
Copyright 2023-2026 - www.financetom.com All Rights Reserved